Drug Search Results
More Filters [+]

Bocidelpar

Alternative Names: Bocidelpar, asp-0367, asp 0367, asp0367
Latest Update: 2024-08-30
Latest Update Note: Clinical Trial Update

Product Description

an orally administered PPAR_ modulator

Mechanisms of Action: PPAR-d Modulator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Fast Track - Mitochondrial Myopathies *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Astellas Pharma
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Bocidelpar

Countries in Clinic: United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 1: Acute Respiratory Distress Syndrome|Healthy Volunteers|Kidney Diseases|Mitochondrial Myopathies|Muscular Dystrophy, Duchenne

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

0367-CL-1111

P1

Completed

Kidney Diseases

2022-11-13

0367-CL-1103

P1

Completed

Mitochondrial Myopathies|Muscular Dystrophy, Duchenne|Acute Respiratory Distress Syndrome

2022-04-30

0367-CL-1102

P1

Completed

Healthy Volunteers

2022-01-11

Recent News Events